# A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

> **NCT06845202** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 144 (estimated)

## Conditions studied

- Obese or Overweight Healthy Volunteers
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** ALN-4324
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06845202
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06845202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06845202, "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT06845202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*